Insomnia Therapeutics Market, By Therapeutics Type (Benzodiazepines, Nonbenzodiazepines, and Antidepressants), By Drug Class, By Route of Administration, By Distribution Channel, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
REPORT HIGHLIGHT
Insomnia Therapeutics Market size was valued at US$ 2,902.32 Million in 2024, expanding at a CAGR of 4.90% from 2025 to 2032.
The insomnia therapeutics market focuses on developing treatments to address both chronic and acute sleep disorders. Factors such as heightened stress, mental health issues, and lifestyle changes have contributed to the rising prevalence of insomnia. According to the CDC, about one in three adults in the U.S. suffers from insufficient sleep. Advances in pharmaceuticals, such as orexin receptor antagonists like lemborexant and daridorexant, are improving treatment outcomes by offering more effective solutions with a lower risk of dependency compared to traditional benzodiazepines. Moreover, cognitive behavioral therapy for insomnia (CBT-I) has gained popularity as a non-pharmacological option, with digital platforms like Somryst receiving FDA approval. Despite these innovations, challenges remain, including potential side effects of sedative-hypnotic medications and concerns about dependency. The growing adoption of AI-powered sleep monitoring devices and wearables offers new opportunities for personalized, data-driven treatment approaches. As the awareness of sleep health continues to rise, demand for safer and more effective insomnia treatments is expected to grow.
Insomnia Therapeutics Market- Market Dynamics
Ø Increasing Prevalence of Mental Health Disorders Boosting Demand for Insomnia Therapeutics
The rising prevalence of mental health disorders is significantly fueling the demand for insomnia therapeutics, as conditions like anxiety, depression, and stress-related disorders often lead to sleep disturbances. According to the World Health Organization (WHO), over 280 million people worldwide suffer from depression, with sleep issues being a common symptom. The National Institute of Mental Health (NIMH) also points out that individuals with anxiety disorders are more likely to develop chronic insomnia. As a result, there is an increasing adoption of cognitive behavioral therapy for insomnia (CBT-I) as a primary treatment option, alongside advancements in pharmacological therapies like dual orexin receptor antagonists, which offer better safety profiles than traditional sedatives. Additionally, digital therapeutics such as the FDA-approved Somryst are becoming integral to mental health treatment plans, offering accessible, non-pharmacological solutions. As the connection between mental health and sleep disorders becomes more widely recognized, healthcare providers and pharmaceutical companies are focusing on developing more personalized and effective insomnia treatments.
Insomnia Therapeutics Market- Segmentation Analysis:
The Global Insomnia Therapeutics Market is segmented on the basis of Therapeutics Type, Drug Class, Route of Administration, Distribution Channel, and Region.
The insomnia therapeutics market is divided into five key categories based on Therapeutic Type: Benzodiazepines, Nonbenzodiazepines, Antidepressants, Orexin Antagonists, Melatonin Antagonists, and Others. Nonbenzodiazepines lead the market due to their high efficacy and lower risk of dependence compared to traditional benzodiazepines. According to a 2019 report by the U.S. Food and Drug Administration (FDA), nonbenzodiazepine drugs such as zolpidem and eszopiclone are preferred by healthcare providers due to their lower incidence of side effects and reduced dependency risks. Orexin antagonists follow, gaining popularity as safer alternatives, particularly for patients with chronic insomnia. A recent study published by the National Institutes of Health (NIH) indicated that orexin receptor antagonists are effective in improving sleep quality while presenting a lower risk of abuse or addiction. Antidepressants are commonly prescribed for patients suffering from comorbid insomnia, particularly those with underlying mental health conditions like depression and anxiety. According to the National Sleep Foundation, approximately 40% of individuals with insomnia also experience depression, leading to widespread use of antidepressants such as trazodone and amitriptyline. Despite concerns regarding their dependency potential, benzodiazepines remain in use, especially in acute cases of insomnia or short-term treatment. The Centers for Disease Control and Prevention (CDC) reports that benzodiazepines are still frequently prescribed for sleep disturbances, but increasing awareness about their risks is pushing healthcare professionals to recommend alternatives. Melatonin antagonists and other therapies are more specialized, catering to specific patient needs, such as those with circadian rhythm disorders. According to FDA data, melatonin receptor antagonists have shown promise in regulating sleep patterns for patients with jet lag or shift-work disorder.
The market is also divided into six categories based on Drug Class: Benzodiazepines, Non-Benzodiazepine Hypnotics, Melatonin Receptor Agonists, Orexin Receptor Antagonists, and Antidepressants. Non-Benzodiazepine Hypnotics dominate the market due to their effectiveness and reduced risk of dependence. According to the FDA, the approval and widespread use of non-benzodiazepine hypnotics like zolpidem have helped address the growing need for safer sleep medications with fewer side effects. Orexin Receptor Antagonists are rapidly gaining market share, driven by their effectiveness in promoting sleep without the dependency risks associated with benzodiazepines. The American Sleep Association (ASA) highlights that orexin antagonists like suvorexant are particularly beneficial for patients with chronic insomnia who are seeking long-term, non-habit forming treatments. Antidepressants are widely used in cases of insomnia associated with mental health disorders such as depression or anxiety. According to the American Psychiatric Association (APA), antidepressants are prescribed to roughly 30% of individuals suffering from insomnia, especially for those with co-occurring psychiatric conditions. Benzodiazepines and Melatonin Receptor Agonists remain in niche segments. Despite the known risks of addiction and tolerance, benzodiazepines are still widely prescribed for short-term insomnia treatment, particularly in cases of severe sleep disturbances. The National Institute on Drug Abuse (NIDA) notes that while the use of benzodiazepines is declining due to dependency concerns, they are still crucial in managing acute sleep disorders. Meanwhile, Melatonin Receptor Agonists are increasingly used for patients who need to reset their sleep-wake cycle, such as those suffering from insomnia related to jet lag or shift work disorder. The World Health Organization (WHO) reports that melatonin agonists show promise in managing circadian rhythm disorders, benefiting a growing segment of the population engaged in irregular work schedules.
Insomnia Therapeutics Market- Geographical Insights
North America leads the insomnia therapeutics market, driven by a high prevalence of sleep disorders, increasing mental health issues, and robust healthcare infrastructure. The U.S. in particular has seen significant adoption of treatments like cognitive behavioral therapy for insomnia (CBT-I) and prescription sleep aids, with new-generation drugs such as daridorexant gaining FDA approval. Europe closely follows, with rising awareness of sleep disorders and government-supported mental health initiatives fueling the demand for advanced therapeutics. Countries such as Germany, the UK, and France are increasingly integrating digital therapeutics, including AI-powered sleep monitoring solutions. In the Asia-Pacific region, factors like lifestyle changes, urbanization, and work-related stress contribute to the growing insomnia burden, especially in China, Japan, and India. The use of herbal and alternative remedies is also on the rise, marking a unique trend in the region. Meanwhile, Latin America and the Middle East & Africa are emerging markets, where expanding healthcare access and awareness initiatives are gradually increasing the adoption of both pharmaceutical and non-pharmaceutical insomnia treatments.
Insomnia Therapeutics Market- Competitive Landscape:
The insomnia therapeutics market is highly competitive, with a mix of established pharmaceutical companies, digital health innovators, and emerging biotech firms focusing on breakthrough treatment solutions. Leading pharmaceutical companies like Merck & Co., Eisai Co., and Idorsia Pharmaceuticals are advancing next-generation insomnia medications, including dual orexin receptor antagonists such as suvorexant and daridorexant, which offer safer profiles compared to traditional sedatives. Jazz Pharmaceuticals and Pfizer are also expanding their portfolios in sleep disorder treatments. The digital therapeutics sector is gaining momentum, with FDA-approved solutions like Pear Therapeutics’ Somryst offering non-drug alternatives through CBT-I. Additionally, startups and technology companies are innovating AI-driven sleep monitoring devices and wearable technologies to provide personalized treatment options. Despite these advancements, challenges such as drug dependency concerns, regulatory hurdles, and competition from alternative treatments like herbal remedies continue to shape market dynamics. Strategic collaborations, product innovation, and expanding distribution channels remain key tactics for companies looking to strengthen their position in the insomnia therapeutics market.
Recent Developments:
v In July 2020, Eisai launched DAYVIGO® (lemborexant) in Japan, a dual orexin receptor antagonist for treating insomnia. The drug facilitates both sleep onset and maintenance, with Phase III trials showing better sleep outcomes compared to placebo and zolpidem. The primary side effects include somnolence, headache, and dizziness.
v In December 2024, Shionogi and Nxera Pharma introduced QUVIVIQ™ (daridorexant) in Japan, a new treatment for adults with insomnia. This oral medication selectively blocks orexin receptors, promoting sleep by reducing wakefulness. Shionogi will oversee its distribution and sales.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL INSOMNIA THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
Ø Astellas Pharma Inc.
Ø Dr. Reddy\'s Laboratories Ltd.
Ø Eisai Co., Ltd.
Ø Lupin Limited
Ø Merck & Co., Inc.
Ø Mylan N.V.
Ø Paratek Pharmaceuticals, Inc.
Ø Pernix Therapeutics Holdings, Inc.
Ø Pfizer Inc.
Ø Sanofi S.A.
Ø Sumitomo Dainippon Pharma Co., Ltd.
Ø Sun Pharmaceutical Industries Ltd.
Ø Takeda Pharmaceutical Company Limited
Ø Teva Pharmaceutical Industries Ltd.
Ø Torrent Pharmaceuticals Ltd.
Ø Vanda Pharmaceuticals Inc.
Ø Others
GLOBAL INSOMNIA THERAPEUTICS MARKET, BY THERAPEUTICS TYPE- MARKET ANALYSIS, 2019 - 2032
Ø Benzodiazepines
Ø Nonbenzodiazepines
Ø Antidepressants
Ø Orexin Antagonists
Ø Melatonin Antagonists
Ø Others
GLOBAL INSOMNIA THERAPEUTICS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032
Ø Benzodiazepines
Ø Non-Benzodiazepine Hypnotics
Ø Melatonin Receptor Agonists
Ø Orexin Receptor Antagonists
Ø Antidepressants
GLOBAL INSOMNIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032
Ø Oral
Ø Sublingual
Ø Intravenous
Ø Transdermal
Ø Nasal
GLOBAL INSOMNIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032
Ø Hospital Pharmacies
Ø Retail Pharmacies
Ø Online Pharmacies
Ø Clinics
Ø Wellness Centers
GLOBAL INSOMNIA THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
Ø North America
o U.S.
o Canada
Ø Europe
o Germany
o UK
o France
o Italy
o Spain
o The Netherlands
o Sweden
o Russia
o Poland
o Rest of Europe
Ø Asia Pacific
o China
o India
o Japan
o South Korea
o Australia
o Indonesia
o Thailand
o Philippines
o Rest of APAC
Ø Latin America
o Brazil
o Mexico
o Argentina
o Colombia
o Rest of LATAM
Ø The Middle East and Africa
o Saudi Arabia
o UAE
o Israel
o Turkey
o Algeria
o Egypt
o Rest of MEA
TABLE OF CONTENT
1. Insomnia Therapeutics Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Insomnia Therapeutics Market Snippet by Therapeutics Type
2.1.2. Insomnia Therapeutics Market Snippet by Drug Class
2.1.3. Insomnia Therapeutics Market Snippet by Route of Administration
2.1.4. Insomnia Therapeutics Market Snippet by Distribution Channel
2.1.5. Insomnia Therapeutics Market Snippet by Country
2.1.6. Insomnia Therapeutics Market Snippet by Region
2.2. Competitive Insights
3. Insomnia Therapeutics Key Market Trends
3.1. Insomnia Therapeutics Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Insomnia Therapeutics Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Insomnia Therapeutics Market Opportunities
3.4. Insomnia Therapeutics Market Future Trends
4. Insomnia Therapeutics Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Insomnia Therapeutics Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Insomnia Therapeutics Market Landscape
6.1. Insomnia Therapeutics Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Insomnia Therapeutics Market – By Therapeutics Type
7.1. Overview
7.1.1. Segment Share Analysis, By Therapeutics Type, 2024 & 2032 (%)
7.1.2. Benzodiazepines
7.1.3. Nonbenzodiazepines
7.1.4. Antidepressants
7.1.5. Orexin Antagonists
7.1.6. Melatonin Antagonists
7.1.7. Others
8. Insomnia Therapeutics Market – By Drug Class
8.1. Overview
8.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
8.1.2. Benzodiazepines
8.1.3. Non-Benzodiazepine Hypnotics
8.1.4. Melatonin Receptor Agonists
8.1.5. Orexin Receptor Antagonists
8.1.6. Antidepressants
9. Insomnia Therapeutics Market – By Route of Administration
9.1. Overview
9.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
9.1.2. Oral
9.1.3. Sublingual
9.1.4. Intravenous
9.1.5. Transdermal
9.1.6. Nasal
10. Insomnia Therapeutics Market – By Distribution Channel
10.1. Overview
10.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
10.1.2. Hospital Pharmacies
10.1.3. Retail Pharmacies
10.1.4. Online Pharmacies
10.1.5. Clinics
10.1.6. Wellness Centers
11. Insomnia Therapeutics Market– By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
11.2. North America
11.2.1. Overview
11.2.2. Insomnia Therapeutics Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.2.4. North America Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.2.5. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. Insomnia Therapeutics Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.3.5. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.9. UK
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.9.3. UK Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.3.9.4. UK Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.9.5. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.9.6. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.10. France
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.10.3. France Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.3.10.4. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.10.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.10.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.11. Italy
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.11.3. Italy Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.3.11.4. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.11.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.11.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.12. Spain
11.3.12.1. Overview
11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.12.3. Spain Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.3.12.4. Spain Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.12.5. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.12.6. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.13. The Netherlands
11.3.13.1. Overview
11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.13.3. The Netherlands Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.3.13.4. The Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.13.5. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.13.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.14. Sweden
11.3.14.1. Overview
11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.14.3. Sweden Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.3.14.4. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.14.5. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.14.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.15. Russia
11.3.15.1. Overview
11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.15.3. Russia Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.3.15.4. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.15.5. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.15.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.16. Poland
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.16.3. Poland Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.3.16.4. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.16.5. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.17. Rest of Europe
11.3.17.1. Overview
11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.17.3. Rest of the Europe Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.3.17.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.17.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.17.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. Insomnia Therapeutics Key Manufacturers in Asia Pacific
11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.4.4. APAC Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.4.5. APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.6. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.7. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.8. China
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.8.3. China Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.4.8.4. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.8.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.8.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.9. India
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.9.3. India Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.4.9.4. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.9.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.9.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.12.3. Australia Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.4.12.4. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.13. Indonesia
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.13.3. Indonesia Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.4.13.4. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.13.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.13.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.14. Thailand
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.14.3. Thailand Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.4.14.4. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.14.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.14.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.15.3. Philippines Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.4.15.4. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.16. Rest of APAC
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.16.3. Rest of APAC Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.4.16.4. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5. Latin America (LATAM)
11.5.1. Overview
11.5.2. Insomnia Therapeutics Key Manufacturers in Latin America
11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.5.4. LATAM Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.5.5. LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.6. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.11.3. Colombia Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.5.11.4. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.5.12.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa (MEA)
11.6.1. Overview
11.6.2. Insomnia Therapeutics Key Manufacturers in Middle East and Africa
11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.6.4. MEA Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.6.5. MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.6. MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.7. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.10.3. Israel Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.6.10.4. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.11.3. Turkey Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.6.11.4. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.12.3. Algeria Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.6.12.4. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.13.3. Egypt Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.6.13.4. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.14. Rest of MEA
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.14.3. Rest of MEA Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
11.6.14.4. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12. Key Vendor Analysis- Insomnia Therapeutics Industry
12.1. Competitive Dashboard
12.1.1. Competitive Benchmarking
12.1.2. Competitive Positioning
12.2. Company Profiles
12.2.1. Astellas Pharma Inc.
12.2.2. Dr. Reddy\'s Laboratories Ltd.
12.2.3. Eisai Co., Ltd.
12.2.4. Lupin Limited
12.2.5. Merck & Co., Inc.
12.2.6. Mylan N.V.
12.2.7. Paratek Pharmaceuticals, Inc.
12.2.8. Pernix Therapeutics Holdings, Inc.
12.2.9. Pfizer Inc.
12.2.10. Sanofi S.A.
12.2.11. Sumitomo Dainippon Pharma Co., Ltd.
12.2.12. Sun Pharmaceutical Industries Ltd.
12.2.13. Takeda Pharmaceutical Company Limited
12.2.14. Teva Pharmaceutical Industries Ltd.
12.2.15. Torrent Pharmaceuticals Ltd.
12.2.16. Vanda Pharmaceuticals Inc.
12.2.17. Others
13. 360 Degree AnalystView
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
